Figure 4: PCSK9 Treatment Increases Apo(a) Secretion From Primary Human Hepatocytes: An Effect Blocked by Alirocumab

Cells were treated with increasing concentrations of recombinant PCSK9 with or without alirocumab for 72 h. ApoB100 (A) and apo(a) (B) were quantified in the culture medium by enzyme-linked immunosorbent assay and liquid chromatography-tandem mass spectrometry, respectively. *p < 0.05 vs. control (no PCSK9). **p < 0.05 vs. same dose of PCSK9 without alirocumab, using 1-way analysis of variance on rank-transformed values with post-hoc Newman-Keuls test. Histograms represent the mean ± SEM of 3 independent experiments from 2 hepatocyte donors. Abbreviations as in Figure 1.